Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Spike antibodies after vaccination with Pfizer and Oxford vaccines

A preprint discusses the results of a study of antibody responses to the first and second dose of currently available SARS-CoV-2 vaccines, Pfizer and Oxford.

19 May 2021

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

India’s surge in SARS-CoV-2 infections are linked to the new variants B.1.617 and B.1.618, with mutated spike proteins.

19 May 2021

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

A new study has been published on the medRxiv* preprint server which focuses on validating the serological assays using a large cohort of healthcare workers.

19 May 2021

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

In a new study posted to the bioRxiv* preprint server, researchers from the United States report that two iminosugar glucosidase inhibitors have the ability to suppress the replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in tissue culture – at concentrations of at least 100 times lower than required for cytotoxic effects.

19 May 2021

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Researchers in the United States have provided the first evidence that messenger RNA (mRNA)-based vaccines against severe acute respiratory coronavirus 2 (SARS-CoV-2) induce a broader array of antibody subtypes against the viral spike protein than natural infection does.

19 May 2021

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

Researchers from Germany and the USA recently investigated the cellular and humoral immune responses of patients with IMIDs on immunomodulatory treatment to mRNA COVID-19 vaccines. The research is published on the medRxiv* preprint server.

19 May 2021

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

COVID-19, the coronavirus disease of 2019, is one of the worst pandemics in human history. It emerged in December 2019 and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nearly 164 million SARS-CoV-2 infections and 3.4 million deaths have been reported globally since the beginning of the pandemic, which is still raging in many countries.

18 May 2021

Potent antibody with unique genetic signature and spike recognition mechanism neutralizes SARS-CoV-2

In a new study, researchers used an antibody discovery technology to identify a new potently neutralizing antibody with a unique mode of SARS-CoV-2 recognition. They reported their results on the bioRxiv preprint server.

18 May 2021

Robust T cell and humoral immune response to SARS-CoV-2 in patients with immunodeficiency

A study of immune-deficient adults and children has shown that patients who fail to respond positively to infections and vaccinations have robust humoral immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) structural proteins.

18 May 2021

SARS-CoV-2 B.1.1.420 and B.1.617.1 immune escape variants reported in France

Researchers discovered the first N440K variant and the new E484Q and L452R Indian variants isolated in France in a recent study. They presented the genetic mutations in the isolated genomes and the phylogenetic tree, including these strains among different SARS-CoV-2 clades. This work is posted on the bioRxiv preprint server.

18 May 2021

New imaging technique helps reveal the best antibodies for COVID-19 detection

Vaccines are turning the tide of the pandemic, but the risk of infection is still present in some situations. If you want to visit a friend, get on a plane, or go see a movie, there is no highly accurate, instant test that can tell you right then and there whether or not you have a SARS-CoV-2 infection.

18 May 2021

SpaceX study profiles evolution of antibody response during COVID-19 infection

New research published on the preprint server bioRxiv* suggests S2-specific antibody responses are critical in recovering from mild to severe COVID-19 infection. Compared to patients who died within 28 days of their COVID-19 diagnosis, patients who produced a wide range of S2-specific responses were more likely to survive.

18 May 2021

Moderna's COVID-19 vaccine elicits six-month antibody responses to variants

Researchers in the United States have demonstrated the long-term durability of the antibody responses elicited by Moderna’s mRNA-1273 vaccine against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 May 2021

Researchers investigate immune molecule that helps protect transplanted kidneys

Looking to improve organ transplant success, researchers are working to learn more about how an immune molecule, which also protects a fetus, helps protect some transplanted kidneys, and to develop a synthetic version of that molecule that could help more patients.

18 May 2021

Stabilizing mutations in SARS-CoV-2 immunogens improve vaccine design

Researchers in the United States have developed stabilized immunogens presenting the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may improve the scalability of RBD-based coronavirus vaccines.

18 May 2021

Milder COVID-19 in children may be due to higher memory B cells responses to SARS-CoV-2

A new research paper published in the journal Science explores the differences in coronavirus-specific B memory cell repertoires in children versus adults, as well as the functional importance of this discovery.

18 May 2021

New technology tricks tumors to eliminate itself through the production of anti-cancer agents

Scientists at the University of Zurich have modified a common respiratory virus, called adenovirus, to act like a Trojan horse to deliver genes for cancer therapeutics directly into tumor cells. Unlike chemotherapy or radiotherapy, this approach does no harm to normal healthy cells.

18 May 2021

COVID-19 mRNA vaccines safe and effective for pregnant and breastfeeding women

The current coronavirus disease 2019 (COVID-19) pandemic has brought untold devastation in its wake, with its rapid and asymptomatic spread to hundreds of millions of people the world over. Vaccines have been hailed as the way out of this situation, and a dozen or so are being rolled out in many different countries.

18 May 2021

Breastfeeding safe and beneficial in SARS-CoV-2 infection

\With the onset of the coronavirus disease 2019 (COVID-19) pandemic, hundreds of millions of people became infected worldwide, including thousands of pregnant women near term. The question of vertical transmission to the infant via the placenta or breast milk was very real, leading to a near-total ban on breastfeeding in this group.

17 May 2021

ACROBiosystems makes donations to BEI Resources, accelerating the process of attacking SARS-CoV-2 variants globally

Multiple SARS-CoV-2 variants are emerging and circulating globally; the battle against COVID-19 pandemic is still challenging. Recently, ACROBiosystems donated SARS-CoV-2 mutant proteins to BEI Resources, a NIAID funded bioresource program, joining in the collective effort in attacking SARS-CoV-2 variants globally.

From ACROBiosystems 17 May 2021

Antibody News and Research

Further Reading

Spike antibodies after vaccination with Pfizer and Oxford vaccines

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Methotrexate impairs immunogenicity of BNT162b2 SARS-CoV-2 vaccine in patients with immune-mediated inflammatory diseases

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

Potent antibody with unique genetic signature and spike recognition mechanism neutralizes SARS-CoV-2

Robust T cell and humoral immune response to SARS-CoV-2 in patients with immunodeficiency

SARS-CoV-2 B.1.1.420 and B.1.617.1 immune escape variants reported in France

New imaging technique helps reveal the best antibodies for COVID-19 detection

SpaceX study profiles evolution of antibody response during COVID-19 infection

Moderna's COVID-19 vaccine elicits six-month antibody responses to variants

Researchers investigate immune molecule that helps protect transplanted kidneys

Stabilizing mutations in SARS-CoV-2 immunogens improve vaccine design

Milder COVID-19 in children may be due to higher memory B cells responses to SARS-CoV-2

New technology tricks tumors to eliminate itself through the production of anti-cancer agents

COVID-19 mRNA vaccines safe and effective for pregnant and breastfeeding women

Breastfeeding safe and beneficial in SARS-CoV-2 infection

ACROBiosystems makes donations to BEI Resources, accelerating the process of attacking SARS-CoV-2 variants globally

Using single B cell screening to boost antibody discovery eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo